Treatment options for C3 glomerulopathy

Carla M Nester; Richard J Smith

doi:10.1097/mnh.0b013e32835da24c

Back

Journal article

Peer reviewed

Treatment options for C3 glomerulopathy

Carla M Nester and Richard J Smith

Current opinion in nephrology and hypertension, Vol.22(2), pp.231-237

03/2013

DOI: 10.1097/mnh.0b013e32835da24c

PMCID: PMC4437761

PMID: 23318699

View Online

Abstract

The purpose of this review is to discuss emerging nomenclature, review the salient clinicopathological features and describe the therapeutic options available for the treatment of C3 glomerulopathy (C3G). C3G is minimally responsive to traditional immune suppression and randomized controlled trials to support therapy are absent. The burgeoning understanding of the role of the alternative complement pathway in C3G combined with animal data supporting the use of terminal complement blockade and a few reports suggesting that the anticomplement drug eculizumab may offer a therapeutic advantage have triggered great interest in the field of complement-mediated renal disease. Anticellular immune suppression and plasma therapy have limited efficacy in C3G. Data suggest that eculizumab may ameliorate disease in some C3G patients. The limited, recently published cohort data highlight crucial aspects of this group of diseases and support the need for extensive genetic and biomarker research to validate the pathologic mechanisms, delineate the spectrum of disease and guide the design of the rigorous trials to identify effective therapies for the treatment of C3G.

Kidney - drug effects

Kidney - pathology

Complement C3 - metabolism

Humans

Immunosuppressive Agents - therapeutic use

Kidney - immunology

Treatment Outcome

Glomerulonephritis, Membranoproliferative - drug therapy

Young Adult

Glomerulonephritis, Membranoproliferative - immunology

Animals

Complement Pathway, Alternative - drug effects

Adolescent

Adult

Female

Immunosuppressive Agents - adverse effects

Glomerulonephritis, Membranoproliferative - diagnosis

Complement Activation - drug effects

Details

Title: Subtitle: Treatment options for C3 glomerulopathy
Creators: Carla M Nester - Departments of Internal Medicine and Pediatrics, University of Iowa, Iowa City, Iowa, USA. carla-nester@uiowa.edu
Richard J Smith
Resource Type: Journal article
Publication Details: Current opinion in nephrology and hypertension, Vol.22(2), pp.231-237
DOI: 10.1097/mnh.0b013e32835da24c
PMID: 23318699
PMCID: PMC4437761
NLM abbreviation: Curr Opin Nephrol Hypertens
ISSN: 1062-4821
eISSN: 1473-6543
Publisher: Ovid Technologies (Wolters Kluwer Health); England
Grant note: R01 DK074409 / NIDDK NIH HHS DK074409 / NIDDK NIH HHS
Language: English
Date published: 03/2013
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Molecular Physiology and Biophysics; Anatomy and Cell Biology; Nephrology, Dialysis and Transplantation; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Otolaryngology; Internal Medicine
Record Identifier: 9984007196902771

Metrics

26 Record Views

47 Times Cited - Web of Science

See more details